QMS Medical September profit drops 32% as revenue rises
Key highlights
- QMS Medical reported September 2026 consolidated profit of Rs 2.44 crore, down 32% from Rs 3.58 crore a year earlier.
- QMS Medical’s revenue from operations rose 18% year on year to Rs 52.52 crore in the September 2026 quarter.
- QMS Medical’s services sales increased to Rs 24.65 crore from Rs 10.95 crore, while product sales declined to Rs 27.88 crore.
- QMS Medical’s current borrowings rose to Rs 80.34 crore at 30 September 2026 from Rs 67.51 crore at 31 March 2026.
powered by IRIS

QMS Medical Allied Services Limited reported consolidated profit of Rs 2.44 crore for the quarter ended 30 September 2026, down 32% from Rs 3.58 crore a year earlier, although revenue from operations rose 18% to Rs 52.52 crore. Services sales more than doubled, but higher employee and other expenses outweighed revenue growth.
Know QMS Medical Allied Services inside out
Results, valuation, peers and who's buying, in one view.
What were QMS Medical’s September-quarter results?
QMS Medical reported total income of Rs 52.75 crore in the September 2026 quarter, up from Rs 44.92 crore in the September 2025 quarter. Revenue from operations accounted for Rs 52.52 crore, while other income was Rs 41.78 lakh, compared with Rs 21.93 lakh in the prior-year quarter.
Profit before tax fell to Rs 3.33 crore from Rs 4.85 crore a year earlier, and profit for the period declined to Rs 2.44 crore from Rs 3.58 crore. Total tax expense decreased to Rs 81.49 lakh from Rs 1.27 crore, but the lower tax charge did not offset the Rs 1.52 crore reduction in pre-tax profit.
Profit attributable to QMS Medical’s owners was Rs 2.36 crore in the September 2026 quarter, while non-controlling interest was Rs 7.51 lakh. Basic and diluted earnings per share were Rs 1.26, compared with Rs 3.90 a year earlier, on paid-up equity share capital of Rs 19.34 crore.
Which QMS Medical segment drove revenue growth?
QMS Medical’s services business drove the increase in quarterly revenue, with sale of services rising to Rs 24.65 crore in the quarter ended 30 September 2026 from Rs 10.95 crore a year earlier. The company reports healthcare equipment and supplies and services as its two operating segments.
Sale of products moved in the other direction, falling to Rs 27.88 crore from Rs 33.75 crore in the September 2025 quarter. As a result, services supplied nearly half of QMS Medical’s Rs 52.52 crore quarterly revenue from operations, compared with roughly one-quarter in the comparable prior-year period.
The same mix shift was visible against the immediately preceding June 2026 quarter. Services sales increased from Rs 23.49 crore in June to Rs 24.65 crore in September, while product sales fell from Rs 33.37 crore to Rs 27.88 crore and total revenue from operations declined from Rs 56.87 crore to Rs 52.52 crore.
Why did QMS Medical’s profit fall despite higher revenue?
QMS Medical’s total expenses rose by Rs 9.39 crore year on year to Rs 49.46 crore in the September 2026 quarter, exceeding the Rs 7.83 crore increase in total income. This left profit before tax at Rs 3.33 crore, compared with Rs 4.85 crore in the September 2025 quarter.
Employee benefits expense increased to Rs 12.57 crore from Rs 2.00 crore, while other expenses rose to Rs 11.78 crore from Rs 9.16 crore. Depreciation and amortisation increased to Rs 1.60 crore from Rs 1.06 crore, and finance cost rose to Rs 1.86 crore from Rs 1.38 crore.
Purchase of stock-in-trade declined to Rs 19.57 crore from Rs 26.97 crore, partly moderating the expense increase. However, the disclosed expense lines show that the increase in employee benefits, other expenses, depreciation and finance cost was larger than the reduction in stock purchases.
Got a follow-up? Ask IRIS
How did QMS Medical perform in the first half of 2026-27?
QMS Medical reported revenue from operations of Rs 109.30 crore for the six months ended 30 September 2026, up from Rs 91.20 crore in the corresponding six months of 2025. Services sales rose to Rs 48.14 crore from Rs 22.04 crore, while product sales declined to Rs 61.25 crore from Rs 69.15 crore.
First-half profit for the period was Rs 6.40 crore, down from Rs 6.74 crore in the comparable prior-year period, while profit before tax declined to Rs 8.83 crore from Rs 9.34 crore. The half-year result was supported by Rs 3.96 crore of profit in the June 2026 quarter, versus Rs 2.44 crore in the September quarter.
Total expenses for the six months ended September 2026 increased to Rs 101.20 crore from Rs 82.40 crore a year earlier. Employee benefits expense rose to Rs 23.74 crore from Rs 6.12 crore, and other expenses increased to Rs 22.99 crore from Rs 19.97 crore, while purchase of stock-in-trade fell to Rs 40.43 crore from Rs 54.70 crore.
What does QMS Medical’s September balance sheet show?
QMS Medical reported total assets of Rs 217.86 crore at 30 September 2026, compared with Rs 211.02 crore at 31 March 2026. Trade receivables increased to Rs 71.89 crore from Rs 64.98 crore, inventories rose to Rs 47.52 crore from Rs 45.92 crore, and cash and cash equivalents declined to Rs 83 lakh from Rs 1.19 crore.
Total equity was Rs 101.05 crore at 30 September 2026, down from Rs 109.87 crore at 31 March 2026. Other equity declined to Rs 71.56 crore from Rs 80.76 crore, while minority interest increased to Rs 10.15 crore from Rs 9.77 crore.
Current borrowings rose to Rs 80.34 crore from Rs 67.51 crore during the six-month period, while non-current borrowings decreased to Rs 6.75 crore from Rs 6.97 crore. QMS Medical’s unaudited consolidated results include Saarathi Healthcare Private Limited and Vivra Wellness Private Limited, and the auditor issued an unmodified limited-review conclusion on 14 November 2026.
What corporate actions has QMS Medical disclosed?
QMS Medical’s board approved a composite scheme on 25 September 2026 to demerge its healthcare services business, together with the healthcare services business of Health Care at Home India Private Limited, into Saarathi Healthcare Private Limited. Under the proposed arrangement, Saarathi would issue one Rs 10 equity share for every one Rs 10 equity share held in QMS Medical, and QMS Medical’s existing shareholding in Saarathi would be cancelled.
Saarathi intends to seek a listing on the National Stock Exchange of India Limited, but the scheme requires approval from shareholders, creditors, the exchange, the Securities and Exchange Board of India, the National Company Law Tribunal and other authorities. QMS Medical said no effect of the scheme had been recorded in the September 2026 financial results.
The board also approved the proposed acquisition of 100% of BeamOptics Scientific Private Limited and executed a binding memorandum of understanding on 25 September 2026. Consideration is to be based on an independent valuer’s report and may be paid in cash, through a share swap or both, subject to transaction conditions and National Company Law Tribunal approval of the scheme.
Conclusion
QMS Medical’s September 2026 quarter combined an 18% increase in revenue with a 32% fall in consolidated profit. Services sales rose to Rs 24.65 crore and partly replaced lower product sales, but total expenses increased faster than total income, reducing profit before tax to Rs 3.33 crore.
The next disclosed milestones are approvals for the proposed Saarathi demerger and the conditions attached to the proposed BeamOptics acquisition. QMS Medical has said that neither transaction had affected the September 2026 financial results, while Saarathi’s intended National Stock Exchange listing remains conditional on shareholder, creditor and regulatory approvals.


